EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey

Kimberly S Lakin iD, Antonia Valenzuela iD, John D Pauling iD, Deanna P Jannat-Khah iD, Kelsey Gripp iD, Oshmita Golam iD, Robyn T Domsic iD, Robert F Spiera iD, Jessica K Gordon iD

Rheumatology Advances in Practice · 15.06.2026 · 10 (3)

DOI: 10.1093/rap/rkag086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 21.07.2026. Verfasst von Kimberly S Lakin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Hospital for Special Surgery, New York, NY, USA. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NCATS NIH HHS, Weill Cornell Medicine Clinical and Translational Science Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate contemporary global treatment of diffuse cutaneous systemic sclerosis (dcSSc) skin by SSc specialists.

Methods

An anonymous survey was distributed via the Scleroderma Clinical Trials Consortium, European Scleroderma Trials and Research Group (EUSTAR), and Collaborative National Quality and Efficacy Registry (CONQUER) distribution lists between June and September 2025. The survey comprised four sections: Demographics, Treatment of dcSSc Skin, Impact of Recent Guidelines, and Clinical Trials.

Results

Responses included 103 physicians (93 completed): 43% North America, 31% Europe, 15% South America and 12% elsewhere. The majority practice within an SSc centre (80%) and participate in clinical trials (84%). Mycophenolate mofetil (MMF) was preferred first-line treatment (71%) for dcSSc without ILD, rising to 92% for dcSSc with mild/non-progressive ILD. For active skin involvement despite MMF, trial referral was preferred as next step irrespective of ILD (59% without ILD and 58% with ILD). Treatment preferences have evolved, with 40% increasing MMF use and 47% decreasing methotrexate use, over the previous 2–3 years. Biologic use has increased, with 56% and 37% reporting increasing rituximab and tocilizumab use, respectively. For dcSSc without ILD, 85% have prescribed rituximab, and 65% have prescribed tocilizumab. Biologic availability has impacted trial enrolment (73% agreement). Treatment decision-making for dcSSc skin involvement has been materially influenced by recent BSR and/or EULAR guidelines (43% agreement).

Conclusion

MMF is preferred first-line for dcSSc. In the absence of compelling scientific justification for combination or step-up immunomodulatory approaches, trial referral is currently the preferred next treatment option. Biologic use is increasing, which impacts trial enrolment.

Schlagwörter

Stichwörter der Autor:innen

biologic therapydiffuse cutaneous systemic sclerosisimmunosuppressive therapiesphysician surveyreal-world practicesclerodermaskin fibrosissystemic sclerosistreatment guidelines

Autor:innen und Institutionen

  • Department of Medicine, Hospital for Special Surgery, New York, NY, USA.
  • Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Department of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Department of Clinical Immunology and Rheumatology, UC CHRISTUS Healthcare System, Santiago, Chile.
  • Department of Medicine, North Bristol NHS Trust, Bristol, UK.
  • Division of Rheumatology & Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

ORCID-Profile: Kimberly S Lakin, Antonia Valenzuela, John D Pauling, Deanna P Jannat-Khah, Kelsey Gripp, Oshmita Golam, Robyn T Domsic, Robert F Spiera, Jessica K Gordon

Förderung

  • NIAMS NIH HHS
  • NCATS NIH HHS
  • Weill Cornell Medicine Clinical and Translational Science Centre

Zitieren

APA

Lakin, K. S., Valenzuela, A., Pauling, J. D., Jannat-Khah, D. P., Gripp, K., Golam, O., Domsic, R. T., Spiera, R. F., & Gordon, J. K. (2026). Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey. Rheumatology Advances in Practice, 10(3). https://doi.org/10.1093/rap/rkag086

Vancouver

Lakin KS, Valenzuela A, Pauling JD, Jannat-Khah DP, Gripp K, Golam O, et al. Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey. Rheumatology Advances in Practice. 2026;10(3). doi:10.1093/rap/rkag086

BibTeX
@article{Lakin2026,
  author = {Lakin, Kimberly S and Valenzuela, Antonia and Pauling, John D and Jannat-Khah, Deanna P and Gripp, Kelsey and Golam, Oshmita and Domsic, Robyn T and Spiera, Robert F and Gordon, Jessica K},
  title = {Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey},
  journal = {Rheumatology Advances in Practice},
  year = {2026},
  volume = {10},
  number = {3},
  doi = {10.1093/rap/rkag086}
}
Kostenlos starten →